drugset
drugset / Trial / NCT05699239

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT05699239 ↗

Phase 2 Completed 326 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis

Timeline

Start
2023-02-08
Primary completion
2023-12-26
Completion
2023-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 10 mg Oral
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 30 mg Oral
Subject TS-172 Unknown 60 mg Oral

Indications

hyperphosphatemia